Pharma Patents Are Vulnerable In Canada As Lilly Loses NAFTA Challenge
Executive Summary
Tribunal finds Lilly did not prove that Canada's promise utility doctrine discriminates against pharmaceutical patents; 25 pharma patents have been invalidated in past decade.
You may also be interested in...
EU Under Fire Again For Pursuing Investor-State Dispute Settlement-like Mechanisms
The EU is once again facing criticism for its pursuit of investor-state dispute settlement-like mechanisms.
AstraZeneca Defeats Canada's Patent 'Promise Doctrine' Through Court, Not NAFTA
Supreme Court of Canada says promise doctrine is not correct approach to determine if a patent has sufficient utility; doctrine has been used to invalidate patents on 22 medicines.
Could Trump’s NAFTA Renegotiation Hit Canadian Drug Price Controls?
Thanks to forthcoming NAFTA renegotiations, the US could put Canada under pressure to rethink its plans to curb excessive pricing.